Immuno-oncology, vaccine development, and biotech research by Agenus
Agenus advances plans for Phase 3 ROBBIN study with global site preparations
Agenus is preparing to launch its Phase 3 ROBBIN study, with recent site preparation activities in São Paulo, Brazil. The company’s medical team joined investigators and site teams to lay ...
Phase 2 colon cancer data from Agenus show 72 percent pathologic complete response
Agenus announced new phase 2 clinical data at ESMO26 showing that 83 percent of patients with locally advanced dMMR colon cancer who received BOT and BAL before surgery achieved a major pathologic ...
Agenus to announce third quarter 2026 financial results on November 5
Agenus has announced it will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the U.S. financial markets open. The company shared the planned announcement ...
Armenia grants first authorization for Agenus BOT plus BAL therapy in MSS mCRC
Agenus announced that Armenia has granted its first marketing authorizations for BOT plus BAL in adults with previously treated microsatellite stable metastatic colorectal cancer (MSS mCRC) ...
Agenus reports 48 percent 3 year overall survival in ovarian cancer study
Agenus presented new three-year follow-up data from its Phase 1b trial of BOT plus BAL in patients with recurrent ovarian cancer. The estimated overall survival was 48 percent at three years, ...
Agenus brings long term survivor data on BOT plus BAL to SITC2026
Agenus announced plans to present new research findings on its BOT plus BAL therapy for colorectal cancer at the SITC2026 conference. The presentation will include long term survivor data in ...
Agenus provides update on ROBBIN Phase 3 execution and BOT+BAL immunotherapy program
Agenus has released updates on the execution of its ROBBIN Phase 3 clinical trial and developments in its BOT+BAL immunotherapy initiative targeting colorectal cancer. The company also discussed ...
Agenus schedules premarket release of Q2 2026 earnings and development outlook on August 6
Agenus will publish its second quarter 2026 financial results and provide a development update before the start of trading on Thursday, August 6. The forthcoming report will offer investors and ...
Agenus advances BOT plus BAL neoadjuvant trials for CRC and sarcoma at ESMO26
Agenus is expanding its neoadjuvant oncology strategy with three investigator-sponsored posters at ESMO26, focusing on the combination of BOT and BAL therapies. The studies cover neoadjuvant ...
Private placement of 340 million dollars drives Agenus funding for ROBBIN trial
Agenus has announced an oversubscribed private placement of up to 340 million dollars intended to finance the advancement of its planned Phase 3 clinical trial, ROBBIN, for neoadjuvant BOT plus ...
Agenus delivers 33 percent three year OS in MSS mCRC trial with BOT plus BAL
Agenus has released new three year follow up data from its ongoing study evaluating the investigational combination of BOT plus BAL in patients with refractory microsatellite stable metastatic ...
Immune signatures in cold tumors identified by Agenus study
Agenus and the Armenian Bioinformatics Institute have published new research in Oncogene focusing on immune patterns in microsatellite stable (MSS) colorectal cancer tumors. Using transcriptomic ...
Agenus energizes IO development after engagement at ASCO2026 in Chicago
Agenus returned from several days in Chicago at ASCO2026 invigorated to advance immuno-oncology research for patients. The company used the conference to network with IO experts, participate in ...
Agenus reveals durable survival with BOT plus BAL in heavily treated melanoma
Agenus posted updated Phase 2 data for its BOT plus BAL combination therapy in heavily pretreated, advanced checkpoint-refractory melanoma. Median overall survival reached 16.6 months, with 42 ...
